Covid-19 roundup: Despite treatment shortages, some US pharmacies report pile-ups of Merck's antiviral
The federal government has only sent four shipments of Merck’s Covid-19 antiviral molnupiravir (about 400,000 courses in each shipment) nationwide, and already HHS is reporting that some pharmacies are running out of space for the pill because so few people are using it.
Once considered a centerpiece of the US Covid-19 armamentarium, the Merck pill is now piling up on pharmacy shelves as both Pfizer’s pill Paxlovid and GSK/Vir’s monoclonal antibody sotrovimab are recommended for use ahead of molnupiravir.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.